title: Clinical safety of drug-eluting stents in the Korea acute myocardial infarction registry.
abstract: BACKGROUND
  Percutaneous coronary intervention (PCI) with drug-eluting stents (DES) may be useful in patients with acute myocardial infarction (AMI), but safety issues still need to be solved. This study was undertaken to investigate the incidence of major adverse cardiac events (MACE) and stent thrombosis in DES-implanted AMI patients in real-life clinical practice.
  
  
  RESULTS
  On-line registry of AMI cases at the web site www.kamir.or.kr has been performed in 41 primary PCI centers in Korea and between November 2005 and September 2006, 1,541 surviving patients who had been implanted with either Cypher or Taxus stents were enrolled for analysis during a 6-month clinical follow-up. There were 2 groups: group I [834 patients, 61.9+/-11.9 years: sirolimus-eluting stent (Cypher)], group II [707 patients, 62.9+/-12.0 years: paclitaxel-eluting stent (Taxus)]. At both 1 and 6 months the incidence of MACE was not significantly different between the 2 groups. There were 17 cases of stent thrombosis, but the incidence of stent thrombosis was not significantly different between the 2 groups (group I:II=9 (1.1%):8 (1.1%), p=1.000). The stent type, length, number, lesion complexity and diabetes were not significant for the incidence of MACE or stent thrombosis after adjustment.
  
  
  CONCLUSIONS
  MACE and stent thrombosis rates did not differ between 2 types of DES identified in Korea Acute Myocardial Infarction Registry (KAMIR). DES can be used in patients with AMI with a relatively low 6-month MACE rate.
authors.affiliation: Chonbuk National University Research Institute of Medical Science, Jeonju, South Korea.
authors.forename: Sang Rok
authors.initials: SR
authors.lastname: Lee
authors.forename: Myung Ho
authors.initials: MH
authors.lastname: Jeong
authors.forename: Young Keun
authors.initials: YK
authors.lastname: Ahn
authors.forename: Shung Chull
authors.initials: SC
authors.lastname: Chae
authors.forename: Seung Ho
authors.initials: SH
authors.lastname: Hur
authors.forename: Young Jo
authors.initials: YJ
authors.lastname: Kim
authors.forename: In Whan
authors.initials: IW
authors.lastname: Seong
authors.forename: Jei Keon
authors.initials: JK
authors.lastname: Chae
authors.forename: Taek Jong
authors.initials: TJ
authors.lastname: Hong
authors.forename: Jae Young
authors.initials: JY
authors.lastname: Rhew
authors.forename: Myeong Chan
authors.initials: MC
authors.lastname: Cho
authors.forename: Jang Ho
authors.initials: JH
authors.lastname: Bae
authors.forename: Seung Woon
authors.initials: SW
authors.lastname: Rha
authors.forename: Chong Jin
authors.initials: CJ
authors.lastname: Kim
authors.forename: Yang Soo
authors.initials: YS
authors.lastname: Jang
authors.forename: Seung Jung
authors.initials: SJ
authors.lastname: Park
mesh_terms: D000208:Acute Disease; D000368:Aged; D017023:Coronary Angiography; D003328:Coronary Thrombosis / Q000209:etiology; D054855:Drug-Eluting Stents / Q000009:adverse effects*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007723:Korea; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000208:ethnology / Q000503:physiopathology / Q000628:therapy*; D017239:Paclitaxel; D011446:Prospective Studies; D012042:Registries / Q000706:statistics & numerical data*; D012307:Risk Factors; D020123:Sirolimus; D016896:Treatment Outcome
chemical_list: D017239:Paclitaxel; D020123:Sirolimus